Pharma BD Deal Intelligence
A $110M-upfront collaboration where Bristol-Myers Squibb bet up to $3.5B on Prime Medicine's gene-editing platform for prime-edited CAR-T therapies, though Prime's own pipeline unraveled post-deal—25% layoffs, a CEO ouster, and a pivot to liver diseases while BMS kept funding the partnered program.
Gene-editing biotech Prime Medicine strikes up cell therapy R&D alliance with Bristol Myers Squibb with $55M upfront and $55M equity investment.
May 19, 2025: Prime Medicine cut ~25% of workforce and CEO Keith Gottesdiener resigned (CFO Allan Reine promoted to CEO); company refocused on in-vivo liver…
Q1 2026 results (May 7, 2026): BMS prime-edited CAR-T partnership ongoing; related-party collaboration revenue $0.856M (vs $1.454M Q1 2025); $149.2M cash,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS and Prime Medicine formed a strategic collaboration to develop next-generation prime-edited ex vivo T-cell therapies for immunological diseases and cancer. Prime received $110M upfront ($55M cash + $55M equity), with up to $3.5B in milestones ($1.4B development, $2.1B+ commercialization). Prime designs Prime Editor and PASSIGE reagents; BMS handles development, manufacturing, and commercialization. Post-deal, Prime narrowed dramatically: on May 19, 2025 it cut ~25% of staff, replaced CEO Keith Gottesdiener with CFO Allan Reine, and refocused its internal pipeline on in-vivo liver diseases (Wilson's, AATD) while continuing the BMS-funded prime-edited CAR-T program as a core partnered effort. The collaboration remained active as of Prime's Q1 2026 results (May 7, 2026), with $0.856M related-party collaboration revenue in the quarter and $149.2M cash funding operations into 2027.
$7.5B Global CAR-T Market (2024) · $110M BMS Upfront Payment
Prime editing-based cell therapies represent a next-generation approach to engineering T cells for cancer treatment. Unlike traditional CRISPR, prime editing enables precise genetic modifications without double-strand DNA breaks, potentially improving the safety and efficacy of engineered cell therapies for hematologic and solid tumor malignancies.
Prime Medicine's PASSIGE platform combines prime editing with site-specific integrases to stably insert and express genetic cargo in T cells. BMS will leverage this to develop next-generation ex vivo T-cell therapies across oncology and immunology, with Prime providing gene editing strategy and reagent development support.
>$3.5B Total Deal Milestones
The BMS-Prime collaboration extends beyond oncology into immunological diseases, applying prime-edited T-cell therapies to autoimmune and inflammatory conditions. This aligns with growing industry interest in using engineered cell therapies for autoimmune indications.
BMS is responsible for development, manufacturing, and commercialization. Prime receives $55M upfront + $55M equity investment, eligible for >$1.4B development milestones and >$2.1B commercialization milestones plus royalties on net sales.
BMS and Prime Medicine formed collaboration for next-gen prime-edited T-cell therapies in oncology and immunology.
Prime Medicine cut ~25% of staff and replaced CEO Keith Gottesdiener with CFO Allan Reine, refocusing internally on in-vivo liver diseases (Wilson's, AATD). The BMS-partnered prime-edited CAR-T collaboration was explicitly continued as a core partner-funded program.
Preclinical programs. Prime Medicine funded into 1H 2026. 80% gene correction demonstrated in preclinical.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Prime Medicine Inc. (this deal) | 2024 | $3.5B | 68 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2024 deals · Bristol-Myers Squibb Company deals · Gene Therapy deals